JPMorgan upgraded UiPath to Overweight from Neutral with a price target of $28, up from $22, following the Q4 report. The analyst sees the company’s period of annual recurring revenue growth deceleration transitioning into a “stabilized growth trend” while its attachment to generative arterial intelligence automation projects ramps amid ongoing margin improvement. The firm does not expect UiPath shares to “run away” in the near-term, instead it sees an opportunity to accumulate the stock at the current low $20s level.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PATH:
- Uipath Inc Earnings Report: Did it Beat Expectations?
- UiPath (NYSE:PATH) Surges after Stellar Q4 Performance
- Options Volatility and Implied Earnings Moves Today, March 13, 2024
- Options Volatility and Implied Earnings Moves This Week, March 11 – March 15, 2024
- PATH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
